Science Explorer Back to mapMap
Discussion
Institution · Pharmaceutical Product Development (United States)

Most cited papers from Pharmaceutical Product Development (United States)

Pharmaceutical Product Development (United States)

What are the most cited papers from Pharmaceutical Product Development (United States)?

The most cited paper from Pharmaceutical Product Development (United States) is "Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease" (Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst et al., 2012), with 1,628 citations. Next come "Delamanid for Multidrug-Resistant Pulmonary Tuberculosis" (748) and "Heat transfer properties of nanoparticle-in-fluid dispersions (nanofluids) in laminar flow" (729).

Showing 50 of 58 papers. Every paper with more than 153 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst et al. · New England Journal of Medicine Open access 3 Nov 2012 1,628
2 Delamanid for Multidrug-Resistant Pulmonary Tuberculosis Maria Tarcela Gler et al. · New England Journal of Medicine Open access 7 Jun 2012 748
3 Heat transfer properties of nanoparticle-in-fluid dispersions (nanofluids) in laminar flow Ying Yang, Z. George Zhang, Eric A. Grulke et al. · International Journal of Heat and Mass Transfer 12 Dec 2004 729
4 The Asheville Project: Long-Term Clinical and Economic Outcomes of a Community Pharmacy Diabetes Care Program Carole W. Cranor, Barry A. Bunting, Dale B. Christensen · Journal of the American Pharmaceutical Association (1996) Mar 2003 728
5 Challenges in the Development of High Protein Concentration Formulations Steven J. Shire, Zahra Shahrokh, Jun Liu Book chapter 10 Oct 2009 658
6 Antibody Structure and Function: The Basis for Engineering Therapeutics Mark L. Chiu, Dennis R. Goulet, A. I. Teplyakov et al. · Antibodies Open access 3 Dec 2019 658
7 Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst et al. · New England Journal of Medicine Open access 4 Nov 2017 640
8 OS-9 and GRP94 deliver mutant α1-antitrypsin to the Hrd1–SEL1L ubiquitin ligase complex for ERAD John C. Christianson, Thomas A. Shaler, Ryan E. Tyler et al. · Nature Cell Biology Open access 10 Feb 2008 513
9 Reversible Self-Association Increases the Viscosity of a Concentrated Monoclonal Antibody in Aqueous Solution Jun Liu, Mary D.H. Nguyen, James D. Andya et al. · Journal of Pharmaceutical Sciences 28 Jul 2005 443
10 Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study Hagop M. Kantarjian, Deborah Ann Thomas, Jeffrey L. Jorgensen et al. · The Lancet Oncology 20 Feb 2012 413
11 Gene Designer: a synthetic biology tool for constructing artificial DNA segments Alan Villalobos, Jon E. Ness, Claes Gustafsson et al. · BMC Bioinformatics Open access 6 Jun 2006 381
12 Urinary-Cell mRNA Profile and Acute Cellular Rejection in Kidney Allografts Manikkam Suthanthiran et al. · New England Journal of Medicine Open access 4 Jul 2013 371
13 Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia Tomás Berl, Friederike Quittnat-Pelletier, Joseph George Verbalis et al. · Journal of the American Society of Nephrology Open access 25 Feb 2010 352
14 Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers Gopal Krishna, Allen Moton, Lei Ma et al. · Antimicrobial Agents and Chemotherapy Open access 16 Dec 2008 351
15 Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet Suzanne K. Swan, David W. Rudy, Kenneth C. Lasseter et al. · Annals of Internal Medicine 4 Jul 2000 338
16 Reversible Self-Association of a Concentrated Monoclonal Antibody Solution Mediated by Fab–Fab Interaction That Impacts Solution Viscosity Sonoko Kanai, Jun Liu, Thomas W. Patapoff et al. · Journal of Pharmaceutical Sciences 31 Jan 2008 309
17 The APC/C maintains the spindle assembly checkpoint by targeting Cdc20 for destruction Jakob Nilsson, Mona Yekezare, Jeremy Minshull et al. · Nature Cell Biology Open access 9 Nov 2008 304
18 The Influence of Charge Distribution on Self-Association and Viscosity Behavior of Monoclonal Antibody Solutions Sandeep Yadav, Thomas Maxon Laue, Devendra S. Kalonia et al. · Molecular Pharmaceutics 21 Feb 2012 282
19 Tumour necrosis factor antagonists: structure, function, and tuberculosis risks Robert S. Wallis · The Lancet Infectious Diseases 25 Sep 2008 274
20 Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update Lisa M DeTora, Dikran Toroser, Angela Sykes et al. · Annals of Internal Medicine 29 Aug 2022 270
21 Dysregulation of Met receptor tyrosine kinase activity in invasive tumors Alla Danilkovitch‐Miagkova, Berton Zbar · Journal of Clinical Investigation Open access Apr 2002 268
22 ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial Jeffrey Alan Lieberman, Robert E. Davis, Christoph Ulrich Correll et al. · Biological Psychiatry Open access 31 Aug 2015 261
23 Specific interactions in high concentration antibody solutions resulting in high viscosity Sandeep Yadav, Jun Liu, Steven J. Shire et al. · Journal of Pharmaceutical Sciences 24 Aug 2009 255
24 Prevalence of autosomal dominant polycystic kidney disease in the European Union Cynthia J Willey, Jaime D. Blais, Anthony K Hall et al. · Nephrology Dialysis Transplantation Open access 20 Jun 2016 253
25 A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans Graham Molineux, Olaf B. Kinstler, Bob Briddell et al. · Experimental Hematology Open access Dec 1999 245
26 A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial Thierry T.F. Facon et al. · Leukemia Open access 19 Aug 2019 242
27 Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis Eli M. Miloslavsky, Ray Naden, J. W. J. Bijlsma et al. · Annals of the Rheumatic Diseases 29 Jul 2016 238
28 The Asheville Project: Short-term outcomes of a community pharmacy diabetes care program Carole W. Cranor, Dale B. Christensen · Journal of the American Pharmacists Association Nov 2012 238
29 Harnessing nanoparticles for immune modulation Daniel R. Getts, Lonnie D. Shea, Stephen D. Miller et al. · Trends in Immunology ReviewOpen access 15 Jun 2015 234
30 Identification of likely orthologs of tobacco salicylic acid‐binding protein 2 and their role in systemic acquired resistance in Arabidopsis thaliana A. Corina Vlot, Po‐Pu Liu, Robin K. Cameron et al. · The Plant Journal 9 Jul 2008 233
31 Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study Jean‐Michel Molina, Bonaventura Clotet, Jan van Lunzen et al. · The Lancet HIV 9 Mar 2015 230
32 Sensitivity enhancement in liquid chromatography/atmospheric pressure ionization mass spectrometry using derivatization and mobile phase additives Shu-Hong Gao, Zeming Zhang, H. Thomas Karnes · Journal of Chromatography B 18 May 2005 225
33 Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial Martin Markowitz, Ian Frank, Robert M. Grant et al. · The Lancet HIV 22 May 2017 223
34 Methionine, tryptophan, and histidine oxidation in a model protein, PTH: Mechanisms and stabilization Junyan A. Ji, Boyan Zhang, Wilson Cheng et al. · Journal of Pharmaceutical Sciences 19 May 2009 217
35 A Comparative Trial of Didanosine or Zalcitabine after Treatment with Zidovudine in Patients with Human Immunodeficiency Virus Infection Donald I. Abrams, Anne I. Goldman, Cynthia A. Launer et al. · New England Journal of Medicine 10 Mar 1994 217
36 Native Australian fruits — a novel source of antioxidants for food Michael Erich Netzel, Gabriele A. Netzel, Qingguo Tian et al. · Innovative Food Science & Emerging Technologies 2 Apr 2007 214
37 Quality by design case study: An integrated multivariate approach to drug product and process development Jun Huang, Gautam Kaul, C. S. Steve Cai et al. · International Journal of Pharmaceutics 6 Aug 2009 213
38 Lyophilized Drug Product Cake Appearance: What Is Acceptable? Sajal Manubhai Patel, Steven L. Nail, Michael Jon Pikal et al. · Journal of Pharmaceutical Sciences 22 Mar 2017 212
39 Diarrhoeal disease and subsequent risk of death in infants and children residing in low-income and middle-income countries: analysis of the GEMS case-control study and 12-month GEMS-1A follow-on study Myron M. Levine et al. · The Lancet Global Health Open access 18 Dec 2019 210
40 Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy Alan Douglas Tice, Pamela A Hoaglund, David A. Shoultz · The American Journal of Medicine Jun 2003 209
41 Drug Liposome Partitioning as a Tool for the Prediction of Human Passive Intestinal Absorption K. Balon, Bernd U. Riebesehl, Bernhard W. Müller · Pharmaceutical Research Jun 1999 199
42 Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database Paul Brent Watkins, James H. Lewis, Neil Kaplowitz et al. · Drug Safety Open access 18 Jul 2015 197
43 Auristatin Antibody Drug Conjugate Physical Instability and the Role of Drug Payload Yilma T. Adem, Kelly A. Schwarz, Eileen T. Duenas et al. · Bioconjugate Chemistry 24 Feb 2014 195
44 Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion Joseph George Verbalis, Suzanne Myers Adler, Robert W. Schrier et al. · European Journal of Endocrinology Open access 12 Feb 2011 190
45 Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst et al. · Nephrology Dialysis Transplantation Open access 18 Feb 2017 184
46 Pharmacokinetics and Steady-State Bioequivalence of Treprostinil Sodium (Remodulin®) Administered by the Intravenous and Subcutaneous Route to Normal Volunteers Kevin Laliberte, Carl P. Arneson, Roger Jeffs et al. · Journal of Cardiovascular Pharmacology 8 Jul 2004 184
47 Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction James E. Udelson, Cesare Orlandi, John Ouyang et al. · Journal of the American College of Cardiology Open access 29 Oct 2008 182
48 Engineering genes for predictable protein expression Claes Gustafsson, Jeremy Minshull, Sridhar Govindarajan et al. · Protein Expression and Purification Open access 8 Mar 2012 181
49 FAIR data sharing: The roles of common data elements and harmonization Rebecca Daniels Kush, Denise Warzel, Maura Kush et al. · Journal of Biomedical Informatics Open access 11 May 2020 179
50 Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial Florian von Groote-Bidlingmaier et al. · The Lancet Respiratory Medicine Open access 8 Jan 2019 169

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.